Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis
Abstract Background Consistently with their diagnostic and prognostic value, autoantibodies specific for systemic sclerosis (SSc) embedded in immune complexes (ICs) elicited a pro-inflammatory and pro-fibrotic cascade in healthy skin fibroblasts, engaging Toll-like receptors (TLRs) via their nucleic...
Saved in:
Published in | Arthritis research & therapy Vol. 22; no. 1; pp. 1 - 265 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central Ltd
09.11.2020
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Background
Consistently with their diagnostic and prognostic value, autoantibodies specific for systemic sclerosis (SSc) embedded in immune complexes (ICs) elicited a pro-inflammatory and pro-fibrotic cascade in healthy skin fibroblasts, engaging Toll-like receptors (TLRs) via their nucleic acid components. The objective of this study was to investigate the pathogenicity of SSc-ICs in endothelial cells.
Methods
ICs were purified from the sera of SSc patients bearing different autoantibody specificities (antibodies against DNA topoisomerase I, centromeric proteins, RNA polymerase, and Th/To), patients with systemic lupus erythematosus (SLE) and primary anti-phospholipid syndrome (PAPS), or healthy controls (NHS) using polyethylene glycol precipitation. Human umbilical vein endothelial cells (HUVECs) were incubated with ICs, positive and negative controls. mRNA levels of
endothelin-1 (et-1)
,
collagenIα1 (colIα1)
,
interferon (IFN)-α
, and
IFN-β
were investigated by real-time PCR;
et-1
and
il-6
mRNA levels were assessed after pre-treatment with bafilomycin. ICAM-1 expression was evaluated by cell ELISA; secretion of IL-6, IL-8, and transforming growth factor (TGF)-β1 in culture supernatants was measured by ELISA. The expression of Fcγ receptors (CD64, CD32, and CD16) was assessed in endothelial cells at FACS analysis. Intracellular signaling pathways culminating with NFκB, p38MAPK, SAPK-JNK, and Akt were assessed by Western blotting. Healthy skin fibroblasts were stimulated with supernatants from HUVECs incubated with ICs, and TGF-β1 secretion and mRNA levels of
colIα1
and
matrix metalloproteinase (mmp)-1
, protein expression of α smooth muscle actin (α-SMA), and IL-6 were evaluated by Western blotting;
et-1
mRNA levels were assessed in fibroblasts pre-treated with IL-6 and TGF-β inhibitors and stimulated with ATA-ICs.
Results
All SSc stimulated IL-6 secretion; ACA-ICs and anti-Th/To-ICs increased ICAM-1 expression; all SSc-ICs but anti-Th/To-ICs augmented IL-8 levels; all SSc-ICs but ACA-ICs and ARA-ICs upregulated
et-1
, and all SSc-ICs but ARA-ICs affected TGF-β1 secretion. c
olIα1
,
IFN-α
, and
IFN-β
mRNA levels were not affected by any SSc-IC. FcγRII (CD32) and FcγRIII (CD16) were not detectable on HUVECs, while FcγRI (CD64) was minimally expressed. A differential modulation of
tlr
expression was observed:
tlr2
,
tlr3
, and
tlr4
were upregulated by ATA-ICs and ACA-ICs, while anti-Th/To-ICs resulted in
tlr9
upregulation. Pre-treatment with bafilomycin did not affect the upregulation of
et-1
and
il-6
induced by ATA-ICs, ACA-ICs, and anti-Th/To-ICs; a 23% reduction in both genes was reported for ARA-ICs. All SSc-ICs activated p38MAPK and Akt, and all SSc-ICs but ARA-ICs yielded the activation of NFκB; ATA-ICs and ACA-ICs increased the activation rate of both subunits of SAPK-JNK. When healthy skin fibroblasts were stimulated with supernatants from HUVECs incubated with SSc-ICs, TGF-β1 secretion,
colIα1
, α-SMA, and IL-6 expression levels were significantly modulated. Pre-treatment with IL-6 and TGF-β inhibitors prevented
et-1
upregulation induced by ATA-ICs by 85% and 77%, respectively.
Conclusions
These data provide the first demonstration of the pathogenicity of ICs from scleroderma patients with different autoantibodies on the endothelium. Endothelial activation induced by SSc-ICs ultimately led to a pro-fibrotic phenotype in healthy skin fibroblasts. |
---|---|
AbstractList | Abstract Background Consistently with their diagnostic and prognostic value, autoantibodies specific for systemic sclerosis (SSc) embedded in immune complexes (ICs) elicited a pro-inflammatory and pro-fibrotic cascade in healthy skin fibroblasts, engaging Toll-like receptors (TLRs) via their nucleic acid components. The objective of this study was to investigate the pathogenicity of SSc-ICs in endothelial cells. Methods ICs were purified from the sera of SSc patients bearing different autoantibody specificities (antibodies against DNA topoisomerase I, centromeric proteins, RNA polymerase, and Th/To), patients with systemic lupus erythematosus (SLE) and primary anti-phospholipid syndrome (PAPS), or healthy controls (NHS) using polyethylene glycol precipitation. Human umbilical vein endothelial cells (HUVECs) were incubated with ICs, positive and negative controls. mRNA levels of endothelin-1 (et-1), collagenIα1 (colIα1), interferon (IFN)-α, and IFN-β were investigated by real-time PCR; et-1 and il-6 mRNA levels were assessed after pre-treatment with bafilomycin. ICAM-1 expression was evaluated by cell ELISA; secretion of IL-6, IL-8, and transforming growth factor (TGF)-β1 in culture supernatants was measured by ELISA. The expression of Fcγ receptors (CD64, CD32, and CD16) was assessed in endothelial cells at FACS analysis. Intracellular signaling pathways culminating with NFκB, p38MAPK, SAPK-JNK, and Akt were assessed by Western blotting. Healthy skin fibroblasts were stimulated with supernatants from HUVECs incubated with ICs, and TGF-β1 secretion and mRNA levels of colIα1 and matrix metalloproteinase (mmp)-1, protein expression of α smooth muscle actin (α-SMA), and IL-6 were evaluated by Western blotting; et-1 mRNA levels were assessed in fibroblasts pre-treated with IL-6 and TGF-β inhibitors and stimulated with ATA-ICs. Results All SSc stimulated IL-6 secretion; ACA-ICs and anti-Th/To-ICs increased ICAM-1 expression; all SSc-ICs but anti-Th/To-ICs augmented IL-8 levels; all SSc-ICs but ACA-ICs and ARA-ICs upregulated et-1, and all SSc-ICs but ARA-ICs affected TGF-β1 secretion. colIα1, IFN-α, and IFN-β mRNA levels were not affected by any SSc-IC. FcγRII (CD32) and FcγRIII (CD16) were not detectable on HUVECs, while FcγRI (CD64) was minimally expressed. A differential modulation of tlr expression was observed: tlr2, tlr3, and tlr4 were upregulated by ATA-ICs and ACA-ICs, while anti-Th/To-ICs resulted in tlr9 upregulation. Pre-treatment with bafilomycin did not affect the upregulation of et-1 and il-6 induced by ATA-ICs, ACA-ICs, and anti-Th/To-ICs; a 23% reduction in both genes was reported for ARA-ICs. All SSc-ICs activated p38MAPK and Akt, and all SSc-ICs but ARA-ICs yielded the activation of NFκB; ATA-ICs and ACA-ICs increased the activation rate of both subunits of SAPK-JNK. When healthy skin fibroblasts were stimulated with supernatants from HUVECs incubated with SSc-ICs, TGF-β1 secretion, colIα1, α-SMA, and IL-6 expression levels were significantly modulated. Pre-treatment with IL-6 and TGF-β inhibitors prevented et-1 upregulation induced by ATA-ICs by 85% and 77%, respectively. Conclusions These data provide the first demonstration of the pathogenicity of ICs from scleroderma patients with different autoantibodies on the endothelium. Endothelial activation induced by SSc-ICs ultimately led to a pro-fibrotic phenotype in healthy skin fibroblasts. Consistently with their diagnostic and prognostic value, autoantibodies specific for systemic sclerosis (SSc) embedded in immune complexes (ICs) elicited a pro-inflammatory and pro-fibrotic cascade in healthy skin fibroblasts, engaging Toll-like receptors (TLRs) via their nucleic acid components. The objective of this study was to investigate the pathogenicity of SSc-ICs in endothelial cells. ICs were purified from the sera of SSc patients bearing different autoantibody specificities (antibodies against DNA topoisomerase I, centromeric proteins, RNA polymerase, and Th/To), patients with systemic lupus erythematosus (SLE) and primary anti-phospholipid syndrome (PAPS), or healthy controls (NHS) using polyethylene glycol precipitation. Human umbilical vein endothelial cells (HUVECs) were incubated with ICs, positive and negative controls. mRNA levels of endothelin-1 (et-1), collagenI[alpha]1 (colI[alpha]1), interferon (IFN)-[alpha], and IFN-[beta] were investigated by real-time PCR; et-1 and il-6 mRNA levels were assessed after pre-treatment with bafilomycin. ICAM-1 expression was evaluated by cell ELISA; secretion of IL-6, IL-8, and transforming growth factor (TGF)-[beta]1 in culture supernatants was measured by ELISA. The expression of Fc[gamma] receptors (CD64, CD32, and CD16) was assessed in endothelial cells at FACS analysis. Intracellular signaling pathways culminating with NFκB, p38MAPK, SAPK-JNK, and Akt were assessed by Western blotting. Healthy skin fibroblasts were stimulated with supernatants from HUVECs incubated with ICs, and TGF-[beta]1 secretion and mRNA levels of colI[alpha]1 and matrix metalloproteinase (mmp)-1, protein expression of [alpha] smooth muscle actin ([alpha]-SMA), and IL-6 were evaluated by Western blotting; et-1 mRNA levels were assessed in fibroblasts pre-treated with IL-6 and TGF-[beta] inhibitors and stimulated with ATA-ICs. All SSc stimulated IL-6 secretion; ACA-ICs and anti-Th/To-ICs increased ICAM-1 expression; all SSc-ICs but anti-Th/To-ICs augmented IL-8 levels; all SSc-ICs but ACA-ICs and ARA-ICs upregulated et-1, and all SSc-ICs but ARA-ICs affected TGF-[beta]1 secretion. colI[alpha]1, IFN-[alpha], and IFN-[beta] mRNA levels were not affected by any SSc-IC. Fc[gamma]RII (CD32) and Fc[gamma]RIII (CD16) were not detectable on HUVECs, while Fc[gamma]RI (CD64) was minimally expressed. A differential modulation of tlr expression was observed: tlr2, tlr3, and tlr4 were upregulated by ATA-ICs and ACA-ICs, while anti-Th/To-ICs resulted in tlr9 upregulation. Pre-treatment with bafilomycin did not affect the upregulation of et-1 and il-6 induced by ATA-ICs, ACA-ICs, and anti-Th/To-ICs; a 23% reduction in both genes was reported for ARA-ICs. All SSc-ICs activated p38MAPK and Akt, and all SSc-ICs but ARA-ICs yielded the activation of NFκB; ATA-ICs and ACA-ICs increased the activation rate of both subunits of SAPK-JNK. When healthy skin fibroblasts were stimulated with supernatants from HUVECs incubated with SSc-ICs, TGF-[beta]1 secretion, colI[alpha]1, [alpha]-SMA, and IL-6 expression levels were significantly modulated. Pre-treatment with IL-6 and TGF-[beta] inhibitors prevented et-1 upregulation induced by ATA-ICs by 85% and 77%, respectively. These data provide the first demonstration of the pathogenicity of ICs from scleroderma patients with different autoantibodies on the endothelium. Endothelial activation induced by SSc-ICs ultimately led to a pro-fibrotic phenotype in healthy skin fibroblasts. Background Consistently with their diagnostic and prognostic value, autoantibodies specific for systemic sclerosis (SSc) embedded in immune complexes (ICs) elicited a pro-inflammatory and pro-fibrotic cascade in healthy skin fibroblasts, engaging Toll-like receptors (TLRs) via their nucleic acid components. The objective of this study was to investigate the pathogenicity of SSc-ICs in endothelial cells. Methods ICs were purified from the sera of SSc patients bearing different autoantibody specificities (antibodies against DNA topoisomerase I, centromeric proteins, RNA polymerase, and Th/To), patients with systemic lupus erythematosus (SLE) and primary anti-phospholipid syndrome (PAPS), or healthy controls (NHS) using polyethylene glycol precipitation. Human umbilical vein endothelial cells (HUVECs) were incubated with ICs, positive and negative controls. mRNA levels of endothelin-1 (et-1), collagenI[alpha]1 (colI[alpha]1), interferon (IFN)-[alpha], and IFN-[beta] were investigated by real-time PCR; et-1 and il-6 mRNA levels were assessed after pre-treatment with bafilomycin. ICAM-1 expression was evaluated by cell ELISA; secretion of IL-6, IL-8, and transforming growth factor (TGF)-[beta]1 in culture supernatants was measured by ELISA. The expression of Fc[gamma] receptors (CD64, CD32, and CD16) was assessed in endothelial cells at FACS analysis. Intracellular signaling pathways culminating with NFκB, p38MAPK, SAPK-JNK, and Akt were assessed by Western blotting. Healthy skin fibroblasts were stimulated with supernatants from HUVECs incubated with ICs, and TGF-[beta]1 secretion and mRNA levels of colI[alpha]1 and matrix metalloproteinase (mmp)-1, protein expression of [alpha] smooth muscle actin ([alpha]-SMA), and IL-6 were evaluated by Western blotting; et-1 mRNA levels were assessed in fibroblasts pre-treated with IL-6 and TGF-[beta] inhibitors and stimulated with ATA-ICs. Results All SSc stimulated IL-6 secretion; ACA-ICs and anti-Th/To-ICs increased ICAM-1 expression; all SSc-ICs but anti-Th/To-ICs augmented IL-8 levels; all SSc-ICs but ACA-ICs and ARA-ICs upregulated et-1, and all SSc-ICs but ARA-ICs affected TGF-[beta]1 secretion. colI[alpha]1, IFN-[alpha], and IFN-[beta] mRNA levels were not affected by any SSc-IC. Fc[gamma]RII (CD32) and Fc[gamma]RIII (CD16) were not detectable on HUVECs, while Fc[gamma]RI (CD64) was minimally expressed. A differential modulation of tlr expression was observed: tlr2, tlr3, and tlr4 were upregulated by ATA-ICs and ACA-ICs, while anti-Th/To-ICs resulted in tlr9 upregulation. Pre-treatment with bafilomycin did not affect the upregulation of et-1 and il-6 induced by ATA-ICs, ACA-ICs, and anti-Th/To-ICs; a 23% reduction in both genes was reported for ARA-ICs. All SSc-ICs activated p38MAPK and Akt, and all SSc-ICs but ARA-ICs yielded the activation of NFκB; ATA-ICs and ACA-ICs increased the activation rate of both subunits of SAPK-JNK. When healthy skin fibroblasts were stimulated with supernatants from HUVECs incubated with SSc-ICs, TGF-[beta]1 secretion, colI[alpha]1, [alpha]-SMA, and IL-6 expression levels were significantly modulated. Pre-treatment with IL-6 and TGF-[beta] inhibitors prevented et-1 upregulation induced by ATA-ICs by 85% and 77%, respectively. Conclusions These data provide the first demonstration of the pathogenicity of ICs from scleroderma patients with different autoantibodies on the endothelium. Endothelial activation induced by SSc-ICs ultimately led to a pro-fibrotic phenotype in healthy skin fibroblasts. Keywords: Systemic sclerosis, Autoantibodies, Immune complexes, Toll-like receptors, Endothelial cells, Fibrosis, Inflammation BACKGROUNDConsistently with their diagnostic and prognostic value, autoantibodies specific for systemic sclerosis (SSc) embedded in immune complexes (ICs) elicited a pro-inflammatory and pro-fibrotic cascade in healthy skin fibroblasts, engaging Toll-like receptors (TLRs) via their nucleic acid components. The objective of this study was to investigate the pathogenicity of SSc-ICs in endothelial cells. METHODSICs were purified from the sera of SSc patients bearing different autoantibody specificities (antibodies against DNA topoisomerase I, centromeric proteins, RNA polymerase, and Th/To), patients with systemic lupus erythematosus (SLE) and primary anti-phospholipid syndrome (PAPS), or healthy controls (NHS) using polyethylene glycol precipitation. Human umbilical vein endothelial cells (HUVECs) were incubated with ICs, positive and negative controls. mRNA levels of endothelin-1 (et-1), collagenIα1 (colIα1), interferon (IFN)-α, and IFN-β were investigated by real-time PCR; et-1 and il-6 mRNA levels were assessed after pre-treatment with bafilomycin. ICAM-1 expression was evaluated by cell ELISA; secretion of IL-6, IL-8, and transforming growth factor (TGF)-β1 in culture supernatants was measured by ELISA. The expression of Fcγ receptors (CD64, CD32, and CD16) was assessed in endothelial cells at FACS analysis. Intracellular signaling pathways culminating with NFκB, p38MAPK, SAPK-JNK, and Akt were assessed by Western blotting. Healthy skin fibroblasts were stimulated with supernatants from HUVECs incubated with ICs, and TGF-β1 secretion and mRNA levels of colIα1 and matrix metalloproteinase (mmp)-1, protein expression of α smooth muscle actin (α-SMA), and IL-6 were evaluated by Western blotting; et-1 mRNA levels were assessed in fibroblasts pre-treated with IL-6 and TGF-β inhibitors and stimulated with ATA-ICs. RESULTSAll SSc stimulated IL-6 secretion; ACA-ICs and anti-Th/To-ICs increased ICAM-1 expression; all SSc-ICs but anti-Th/To-ICs augmented IL-8 levels; all SSc-ICs but ACA-ICs and ARA-ICs upregulated et-1, and all SSc-ICs but ARA-ICs affected TGF-β1 secretion. colIα1, IFN-α, and IFN-β mRNA levels were not affected by any SSc-IC. FcγRII (CD32) and FcγRIII (CD16) were not detectable on HUVECs, while FcγRI (CD64) was minimally expressed. A differential modulation of tlr expression was observed: tlr2, tlr3, and tlr4 were upregulated by ATA-ICs and ACA-ICs, while anti-Th/To-ICs resulted in tlr9 upregulation. Pre-treatment with bafilomycin did not affect the upregulation of et-1 and il-6 induced by ATA-ICs, ACA-ICs, and anti-Th/To-ICs; a 23% reduction in both genes was reported for ARA-ICs. All SSc-ICs activated p38MAPK and Akt, and all SSc-ICs but ARA-ICs yielded the activation of NFκB; ATA-ICs and ACA-ICs increased the activation rate of both subunits of SAPK-JNK. When healthy skin fibroblasts were stimulated with supernatants from HUVECs incubated with SSc-ICs, TGF-β1 secretion, colIα1, α-SMA, and IL-6 expression levels were significantly modulated. Pre-treatment with IL-6 and TGF-β inhibitors prevented et-1 upregulation induced by ATA-ICs by 85% and 77%, respectively. CONCLUSIONSThese data provide the first demonstration of the pathogenicity of ICs from scleroderma patients with different autoantibodies on the endothelium. Endothelial activation induced by SSc-ICs ultimately led to a pro-fibrotic phenotype in healthy skin fibroblasts. Background Consistently with their diagnostic and prognostic value, autoantibodies specific for systemic sclerosis (SSc) embedded in immune complexes (ICs) elicited a pro-inflammatory and pro-fibrotic cascade in healthy skin fibroblasts, engaging Toll-like receptors (TLRs) via their nucleic acid components. The objective of this study was to investigate the pathogenicity of SSc-ICs in endothelial cells. Methods ICs were purified from the sera of SSc patients bearing different autoantibody specificities (antibodies against DNA topoisomerase I, centromeric proteins, RNA polymerase, and Th/To), patients with systemic lupus erythematosus (SLE) and primary anti-phospholipid syndrome (PAPS), or healthy controls (NHS) using polyethylene glycol precipitation. Human umbilical vein endothelial cells (HUVECs) were incubated with ICs, positive and negative controls. mRNA levels of endothelin-1 (et-1), collagenIα1 (colIα1), interferon (IFN)-α, and IFN-β were investigated by real-time PCR; et-1 and il-6 mRNA levels were assessed after pre-treatment with bafilomycin. ICAM-1 expression was evaluated by cell ELISA; secretion of IL-6, IL-8, and transforming growth factor (TGF)-β1 in culture supernatants was measured by ELISA. The expression of Fcγ receptors (CD64, CD32, and CD16) was assessed in endothelial cells at FACS analysis. Intracellular signaling pathways culminating with NFκB, p38MAPK, SAPK-JNK, and Akt were assessed by Western blotting. Healthy skin fibroblasts were stimulated with supernatants from HUVECs incubated with ICs, and TGF-β1 secretion and mRNA levels of colIα1 and matrix metalloproteinase (mmp)-1, protein expression of α smooth muscle actin (α-SMA), and IL-6 were evaluated by Western blotting; et-1 mRNA levels were assessed in fibroblasts pre-treated with IL-6 and TGF-β inhibitors and stimulated with ATA-ICs. Results All SSc stimulated IL-6 secretion; ACA-ICs and anti-Th/To-ICs increased ICAM-1 expression; all SSc-ICs but anti-Th/To-ICs augmented IL-8 levels; all SSc-ICs but ACA-ICs and ARA-ICs upregulated et-1, and all SSc-ICs but ARA-ICs affected TGF-β1 secretion. colIα1, IFN-α, and IFN-β mRNA levels were not affected by any SSc-IC. FcγRII (CD32) and FcγRIII (CD16) were not detectable on HUVECs, while FcγRI (CD64) was minimally expressed. A differential modulation of tlr expression was observed: tlr2, tlr3, and tlr4 were upregulated by ATA-ICs and ACA-ICs, while anti-Th/To-ICs resulted in tlr9 upregulation. Pre-treatment with bafilomycin did not affect the upregulation of et-1 and il-6 induced by ATA-ICs, ACA-ICs, and anti-Th/To-ICs; a 23% reduction in both genes was reported for ARA-ICs. All SSc-ICs activated p38MAPK and Akt, and all SSc-ICs but ARA-ICs yielded the activation of NFκB; ATA-ICs and ACA-ICs increased the activation rate of both subunits of SAPK-JNK. When healthy skin fibroblasts were stimulated with supernatants from HUVECs incubated with SSc-ICs, TGF-β1 secretion, colIα1, α-SMA, and IL-6 expression levels were significantly modulated. Pre-treatment with IL-6 and TGF-β inhibitors prevented et-1 upregulation induced by ATA-ICs by 85% and 77%, respectively. Conclusions These data provide the first demonstration of the pathogenicity of ICs from scleroderma patients with different autoantibodies on the endothelium. Endothelial activation induced by SSc-ICs ultimately led to a pro-fibrotic phenotype in healthy skin fibroblasts. Abstract Background Consistently with their diagnostic and prognostic value, autoantibodies specific for systemic sclerosis (SSc) embedded in immune complexes (ICs) elicited a pro-inflammatory and pro-fibrotic cascade in healthy skin fibroblasts, engaging Toll-like receptors (TLRs) via their nucleic acid components. The objective of this study was to investigate the pathogenicity of SSc-ICs in endothelial cells. Methods ICs were purified from the sera of SSc patients bearing different autoantibody specificities (antibodies against DNA topoisomerase I, centromeric proteins, RNA polymerase, and Th/To), patients with systemic lupus erythematosus (SLE) and primary anti-phospholipid syndrome (PAPS), or healthy controls (NHS) using polyethylene glycol precipitation. Human umbilical vein endothelial cells (HUVECs) were incubated with ICs, positive and negative controls. mRNA levels of endothelin-1 (et-1) , collagenIα1 (colIα1) , interferon (IFN)-α , and IFN-β were investigated by real-time PCR; et-1 and il-6 mRNA levels were assessed after pre-treatment with bafilomycin. ICAM-1 expression was evaluated by cell ELISA; secretion of IL-6, IL-8, and transforming growth factor (TGF)-β1 in culture supernatants was measured by ELISA. The expression of Fcγ receptors (CD64, CD32, and CD16) was assessed in endothelial cells at FACS analysis. Intracellular signaling pathways culminating with NFκB, p38MAPK, SAPK-JNK, and Akt were assessed by Western blotting. Healthy skin fibroblasts were stimulated with supernatants from HUVECs incubated with ICs, and TGF-β1 secretion and mRNA levels of colIα1 and matrix metalloproteinase (mmp)-1 , protein expression of α smooth muscle actin (α-SMA), and IL-6 were evaluated by Western blotting; et-1 mRNA levels were assessed in fibroblasts pre-treated with IL-6 and TGF-β inhibitors and stimulated with ATA-ICs. Results All SSc stimulated IL-6 secretion; ACA-ICs and anti-Th/To-ICs increased ICAM-1 expression; all SSc-ICs but anti-Th/To-ICs augmented IL-8 levels; all SSc-ICs but ACA-ICs and ARA-ICs upregulated et-1 , and all SSc-ICs but ARA-ICs affected TGF-β1 secretion. c olIα1 , IFN-α , and IFN-β mRNA levels were not affected by any SSc-IC. FcγRII (CD32) and FcγRIII (CD16) were not detectable on HUVECs, while FcγRI (CD64) was minimally expressed. A differential modulation of tlr expression was observed: tlr2 , tlr3 , and tlr4 were upregulated by ATA-ICs and ACA-ICs, while anti-Th/To-ICs resulted in tlr9 upregulation. Pre-treatment with bafilomycin did not affect the upregulation of et-1 and il-6 induced by ATA-ICs, ACA-ICs, and anti-Th/To-ICs; a 23% reduction in both genes was reported for ARA-ICs. All SSc-ICs activated p38MAPK and Akt, and all SSc-ICs but ARA-ICs yielded the activation of NFκB; ATA-ICs and ACA-ICs increased the activation rate of both subunits of SAPK-JNK. When healthy skin fibroblasts were stimulated with supernatants from HUVECs incubated with SSc-ICs, TGF-β1 secretion, colIα1 , α-SMA, and IL-6 expression levels were significantly modulated. Pre-treatment with IL-6 and TGF-β inhibitors prevented et-1 upregulation induced by ATA-ICs by 85% and 77%, respectively. Conclusions These data provide the first demonstration of the pathogenicity of ICs from scleroderma patients with different autoantibodies on the endothelium. Endothelial activation induced by SSc-ICs ultimately led to a pro-fibrotic phenotype in healthy skin fibroblasts. |
ArticleNumber | 265 |
Audience | Academic |
Author | Borghi, Maria Orietta Raschi, Elena Privitera, Daniela Meroni, Pier Luigi Ingegnoli, Francesca Chighizola, Cecilia Beatrice Lonati, Paola Adele Bodio, Caterina |
Author_xml | – sequence: 1 fullname: Raschi, Elena – sequence: 2 fullname: Privitera, Daniela – sequence: 3 fullname: Bodio, Caterina – sequence: 4 fullname: Lonati, Paola Adele – sequence: 5 fullname: Borghi, Maria Orietta – sequence: 6 fullname: Ingegnoli, Francesca – sequence: 7 fullname: Meroni, Pier Luigi – sequence: 8 fullname: Chighizola, Cecilia Beatrice |
BookMark | eNptUsuKFDEULWTEeegPuAq4cVNjXpVUuRCGwcfAgAt1HVLJre40VUmbVA32h_i_3u4e1BYJIeHec899ncvqLKYIVfWS0WvGWvWmMEF1U1NO8QpFa_GkumBSt7USip_99T-vLkvZUMp5x-Wz6lwIplqq2UX184sbIScPebJ12YILQ3DELnOycQ598gEKgakH78GTEEmYpiUCcWnajvADnRP4YGcgEH2a1zAGOxJvJ7uCt8RGAjaPOwIPEOd9OCLI1s7rtIIIJRSSBlJ2ZYYJ05ZDLWh9Xj0d7FjgxeN7VX378P7r7af6_vPHu9ub-9opqua6V0CpkryV2BlXqtFd5511TgIb-kHSTvWeto10XT-0A225ptAILSXnzAOIq-ruyOuT3ZhtDpPNO5NsMAdDyitj8xywLAPKekt7L7X3EtqhZ0p61zEsQXnbN8j17si1XXqcicOGsx1PSE89MazNKj0YrRrZdBoJXj8S5PR9gTKbKRQH42gjpKUYjighW9nsc736B7pJS444KkQp1jaUavkHtbLYQIhDwrxuT2pucGpcs44KRF3_B4XH73eCihsC2k8C-DHA4a5KhuF3j4yavTDNUZgGhWkOwjRC_AIjs9ik |
CitedBy_id | crossref_primary_10_1007_s12016_021_08891_0 crossref_primary_10_1136_annrheumdis_2021_220402 crossref_primary_10_3390_ijms241814287 crossref_primary_10_1038_s41598_022_14004_4 crossref_primary_10_3390_ijms241814385 crossref_primary_10_3390_cells10123402 crossref_primary_10_3389_fimmu_2022_904631 crossref_primary_10_1016_j_smim_2022_101648 crossref_primary_10_1080_13543784_2021_1923693 crossref_primary_10_1097_BOR_0000000000000904 crossref_primary_10_1016_j_jaut_2022_102954 crossref_primary_10_3390_jcm13113022 crossref_primary_10_3390_biomedicines12061331 crossref_primary_10_1038_s41598_023_43350_0 crossref_primary_10_1097_BOR_0000000000000963 crossref_primary_10_1038_s41598_023_31232_4 crossref_primary_10_1111_imr_13331 crossref_primary_10_1007_s12016_022_08946_w crossref_primary_10_1186_s12906_022_03651_9 crossref_primary_10_1136_ard_2023_224184 crossref_primary_10_3389_fmed_2022_849086 crossref_primary_10_1038_s41598_022_21468_x crossref_primary_10_1183_13993003_01949_2023 crossref_primary_10_1016_j_lfs_2022_120874 crossref_primary_10_1016_S1773_035X_24_00172_2 crossref_primary_10_1016_S2665_9913_23_00212_6 crossref_primary_10_1186_s12967_024_05403_4 crossref_primary_10_3389_fmed_2021_822804 crossref_primary_10_3389_frtra_2023_1146040 crossref_primary_10_3390_ijms25052780 crossref_primary_10_1016_j_semarthrit_2022_152136 crossref_primary_10_1097_BOR_0000000000000970 crossref_primary_10_3390_antib12010003 crossref_primary_10_1053_j_ajkd_2022_10_014 crossref_primary_10_3389_fimmu_2022_930970 crossref_primary_10_3390_ijms25116133 |
Cites_doi | 10.1016/j.pharmthera.2018.08.003 10.1002/art.1780400928 10.1038/s41467-019-09683-z 10.1002/art.24038 10.1016/S1074-7613(03)00323-6 10.7326/0003-4819-57-2-305 10.1111/1523-1747.ep12286455 10.1371/journal.pone.0192824 10.1097/BOR.0000000000000200 10.3899/jrheum.100316 10.1093/rheumatology/kez069 10.1002/art.10362 10.1002/art.41153 10.1038/416603a 10.1136/ard.2009.114264 10.1136/annrheumdis-2013-204424 10.1002/art.23486 10.1016/j.autrev.2017.05.024 10.4049/jimmunol.156.4.1549 10.1016/j.yjmcc.2005.12.008 10.1016/0022-1759(86)90028-1 10.1038/s41584-019-0184-z 10.1002/art.22972 10.1084/jem.20031942 10.1189/jlb.1004623 10.1186/s13075-019-1931-x 10.1016/j.imlet.2017.09.001 10.1177/0961203319868531 10.1111/j.1346-8138.2009.00762.x 10.1136/annrheumdis-2018-213518 10.1002/art.37705 10.1172/JCI23025 10.1038/nrrheum.2013.110 10.1016/j.imlet.2017.10.007 10.1186/s13075-018-1689-6 10.1016/j.jaut.2007.07.005 10.1006/bbrc.2002.6449 10.1016/S0140-6736(17)30933-9 10.1186/ar3787 10.1038/s41584-019-0322-7 10.1038/nrrheum.2009.238 10.4081/reumatismo.2018.1049 10.1002/art.1780400322 10.4049/jimmunol.174.9.5740 10.1016/j.autrev.2017.12.010 10.1084/jem.20051696 10.1002/art.40390 10.1046/j.1365-2249.1998.00597.x 10.1111/j.1538-7836.2006.01753.x |
ContentType | Journal Article |
Copyright | COPYRIGHT 2020 BioMed Central Ltd. 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2020 |
Copyright_xml | – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2020 |
DBID | AAYXX CITATION 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s13075-020-02360-3 |
DatabaseName | CrossRef ProQuest Central (Corporate) Proquest Health and Medical Complete ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 7X7 name: Health Medical collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1478-6362 |
EndPage | 265 |
ExternalDocumentID | oai_doaj_org_article_e6ada0bd47dd4e8fb164dc916e06dab5 A642271903 10_1186_s13075_020_02360_3 |
GeographicLocations | Italy United States--US Germany |
GeographicLocations_xml | – name: Italy – name: United States--US – name: Germany |
GrantInformation_xml | – fundername: ; grantid: Ricerca Corrente 2019 – fundername: ; grantid: Progetto Azione A Giovani Ricercatori |
GroupedDBID | --- -5E -5G -A0 -BR .GJ 0R~ 23N 2WC 3V. 4.4 5GY 5VS 6J9 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAYXX ABUWG ACGFS ACJQM ACRMQ ADBBV ADINQ ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CITATION CS3 DIK E3Z EBD EBLON EMOBN F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE HZ~ IAO IHR INH INR ITC KQ8 M1P O5R O5S O9- PGMZT PIMPY PQQKQ PROAC PSQYO RBZ ROL RPM RSV SMD SOJ SV3 TR2 U2A UKHRP WOQ Z7U ABVAZ AFGXO AFNRJ ZA5 7XB 8FK AZQEC DWQXO K9. PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c606t-b6e00642840222665799dcacc4e1fbf4096bd0854c9bf8f08270e53744221dee3 |
IEDL.DBID | RPM |
ISSN | 1478-6362 1478-6354 |
IngestDate | Sun Sep 29 07:07:46 EDT 2024 Tue Sep 17 21:11:53 EDT 2024 Tue Oct 01 09:51:06 EDT 2024 Fri Sep 13 03:48:21 EDT 2024 Thu Feb 22 23:50:14 EST 2024 Wed Jan 10 04:07:03 EST 2024 Thu Sep 12 17:57:14 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c606t-b6e00642840222665799dcacc4e1fbf4096bd0854c9bf8f08270e53744221dee3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-3787-9632 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654597/ |
PMID | 33168071 |
PQID | 2461850074 |
PQPubID | 42876 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_e6ada0bd47dd4e8fb164dc916e06dab5 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7654597 proquest_miscellaneous_2459348455 proquest_journals_2461850074 gale_infotracmisc_A642271903 gale_infotracacademiconefile_A642271903 crossref_primary_10_1186_s13075_020_02360_3 |
PublicationCentury | 2000 |
PublicationDate | 2020-11-09 |
PublicationDateYYYYMMDD | 2020-11-09 |
PublicationDate_xml | – month: 11 year: 2020 text: 2020-11-09 day: 09 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London |
PublicationTitle | Arthritis research & therapy |
PublicationYear | 2020 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | C Corallo (2360_CR34) 2019; 21 G Moroncini (2360_CR33) 2018; 195 Y Katsumata (2360_CR12) 2007; 29 S Serratì (2360_CR27) 2013; 65 J Rosenbaum (2360_CR31) 1988; 72 S O’Reilly (2360_CR47) 2018; 195 M Thiebaut (2360_CR29) 2018; 17 F Basta (2360_CR54) 2019; 58 SI Nihtyanova (2360_CR4) 2010; 6 D Kim (2360_CR30) 2008; 58 LC Pontes-de-Carvalho (2360_CR20) 1986; 89 CB Chighizola (2360_CR9) 2015; 27 MC Hochberg (2360_CR17) 1997; 40 M Gröger (2360_CR39) 1996; 156 G Nocturne (2360_CR10) 2013; 9 AJ Tyndall (2360_CR1) 2010; 69 GA Viglianti (2360_CR43) 2003; 19 Y Mostmans (2360_CR22) 2017; 16 M Koenig (2360_CR23) 2008; 58 P Laplante (2360_CR26) 2005; 174 LF Pan (2360_CR40) 1998; 112 A Ceribelli (2360_CR51) 2010; 37 C Bergua (2360_CR13) 2019; 78 TK Means (2360_CR45) 2005; 115 JJ Oppenheim (2360_CR35) 2005; 77 CP Denton (2360_CR24) 1997; 108 E Raschi (2360_CR14) 2018; 20 MA Raymond (2360_CR25) 2002; 291 A Ahluwalia (2360_CR50) 2018; 13 Y Hamaguchi (2360_CR7) 2010; 37 GP Rodnan (2360_CR2) 1962; 57 JHW Distler (2360_CR15) 2019; 15 MW Boulé (2360_CR46) 2004; 199 J Henderson (2360_CR53) 2018; 192 TE Taher (2360_CR28) 2018; 70 A Ambrosi (2360_CR11) 2012; 14 EC LeRoy (2360_CR16) 1988; 15 R Lande (2360_CR37) 2019; 10 S Miyakis (2360_CR18) 2006; 4 V Kumar (2360_CR48) 2014 F van den Hoogen (2360_CR5) 2013; 72 SP Crampton (2360_CR19) 2007; 3 N Ronda (2360_CR32) 2002; 46 G Robitaille (2360_CR36) 2007; 56 EA Leadbetter (2360_CR44) 2002; 416 N Del Papa (2360_CR21) 1997; 40 J Vollmer (2360_CR42) 2005; 202 ER Volkmann (2360_CR52) 2019; 15 CP Denton (2360_CR3) 2017; 390 MS Chimenti (2360_CR49) 2018; 70 MY Choi (2360_CR8) 2019; 28 D Kim (2360_CR38) 2008; 58 SI Nihtyanova (2360_CR6) 2020; 72 YJ Liang (2360_CR41) 2006; 40 |
References_xml | – volume: 192 start-page: 163 year: 2018 ident: 2360_CR53 publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2018.08.003 contributor: fullname: J Henderson – volume: 40 start-page: 1725 year: 1997 ident: 2360_CR17 publication-title: Arthritis Rheum doi: 10.1002/art.1780400928 contributor: fullname: MC Hochberg – volume: 10 start-page: 1731 issue: 1 year: 2019 ident: 2360_CR37 publication-title: Nat Commun doi: 10.1038/s41467-019-09683-z contributor: fullname: R Lande – volume: 58 start-page: 3902 issue: 12 year: 2008 ident: 2360_CR23 publication-title: Arthritis Rheum doi: 10.1002/art.24038 contributor: fullname: M Koenig – volume: 15 start-page: 202 year: 1988 ident: 2360_CR16 publication-title: J Rheumatol contributor: fullname: EC LeRoy – volume: 19 start-page: 837 issue: 6 year: 2003 ident: 2360_CR43 publication-title: Immunity. doi: 10.1016/S1074-7613(03)00323-6 contributor: fullname: GA Viglianti – volume: 57 start-page: 305 year: 1962 ident: 2360_CR2 publication-title: Ann Intern Med doi: 10.7326/0003-4819-57-2-305 contributor: fullname: GP Rodnan – volume: 108 start-page: 269 issue: 3 year: 1997 ident: 2360_CR24 publication-title: J Invest Dermatol doi: 10.1111/1523-1747.ep12286455 contributor: fullname: CP Denton – volume: 13 start-page: e0192824 issue: 2 year: 2018 ident: 2360_CR50 publication-title: PLoS One doi: 10.1371/journal.pone.0192824 contributor: fullname: A Ahluwalia – volume: 3 start-page: 183 year: 2007 ident: 2360_CR19 publication-title: J Vis Exp contributor: fullname: SP Crampton – volume: 27 start-page: 476 issue: 5 year: 2015 ident: 2360_CR9 publication-title: Curr Opin Rheumatol doi: 10.1097/BOR.0000000000000200 contributor: fullname: CB Chighizola – volume: 37 start-page: 2071 year: 2010 ident: 2360_CR51 publication-title: J Rheumatol doi: 10.3899/jrheum.100316 contributor: fullname: A Ceribelli – volume: 58 start-page: 1303 issue: 7 year: 2019 ident: 2360_CR54 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/kez069 contributor: fullname: F Basta – volume: 46 start-page: 1595 issue: 6 year: 2002 ident: 2360_CR32 publication-title: Arthritis Rheum doi: 10.1002/art.10362 contributor: fullname: N Ronda – volume: 72 start-page: 465 issue: 3 year: 2020 ident: 2360_CR6 publication-title: Arthritis Rheumatol doi: 10.1002/art.41153 contributor: fullname: SI Nihtyanova – volume-title: Robbins and Cotran pathologic basis of disease year: 2014 ident: 2360_CR48 contributor: fullname: V Kumar – volume: 416 start-page: 603 issue: 6881 year: 2002 ident: 2360_CR44 publication-title: Nature. doi: 10.1038/416603a contributor: fullname: EA Leadbetter – volume: 69 start-page: 1809 year: 2010 ident: 2360_CR1 publication-title: Ann Rheum Dis doi: 10.1136/ard.2009.114264 contributor: fullname: AJ Tyndall – volume: 72 start-page: 1747 year: 2013 ident: 2360_CR5 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2013-204424 contributor: fullname: F van den Hoogen – volume: 58 start-page: 2163 year: 2008 ident: 2360_CR30 publication-title: Arthritis Rheum doi: 10.1002/art.23486 contributor: fullname: D Kim – volume: 16 start-page: 774 issue: 8 year: 2017 ident: 2360_CR22 publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2017.05.024 contributor: fullname: Y Mostmans – volume: 156 start-page: 1549 issue: 4 year: 1996 ident: 2360_CR39 publication-title: J Immunol doi: 10.4049/jimmunol.156.4.1549 contributor: fullname: M Gröger – volume: 40 start-page: 412 issue: 3 year: 2006 ident: 2360_CR41 publication-title: J Mol Cell Cardiol doi: 10.1016/j.yjmcc.2005.12.008 contributor: fullname: YJ Liang – volume: 89 start-page: 27 year: 1986 ident: 2360_CR20 publication-title: J Immunol Methods doi: 10.1016/0022-1759(86)90028-1 contributor: fullname: LC Pontes-de-Carvalho – volume: 15 start-page: 208 issue: 4 year: 2019 ident: 2360_CR52 publication-title: Nat Rev Rheumatol doi: 10.1038/s41584-019-0184-z contributor: fullname: ER Volkmann – volume: 56 start-page: 3814 issue: 11 year: 2007 ident: 2360_CR36 publication-title: Arthritis Rheum doi: 10.1002/art.22972 contributor: fullname: G Robitaille – volume: 199 start-page: 1631 issue: 12 year: 2004 ident: 2360_CR46 publication-title: J Exp Med doi: 10.1084/jem.20031942 contributor: fullname: MW Boulé – volume: 77 start-page: 854 issue: 6 year: 2005 ident: 2360_CR35 publication-title: J Leukoc Biol doi: 10.1189/jlb.1004623 contributor: fullname: JJ Oppenheim – volume: 21 start-page: 152 issue: 1 year: 2019 ident: 2360_CR34 publication-title: Arthritis Res Ther. doi: 10.1186/s13075-019-1931-x contributor: fullname: C Corallo – volume: 195 start-page: 2 year: 2018 ident: 2360_CR47 publication-title: Immunol Lett doi: 10.1016/j.imlet.2017.09.001 contributor: fullname: S O’Reilly – volume: 28 start-page: 1285 issue: 11 year: 2019 ident: 2360_CR8 publication-title: Lupus. doi: 10.1177/0961203319868531 contributor: fullname: MY Choi – volume: 37 start-page: 42 issue: 1 year: 2010 ident: 2360_CR7 publication-title: J Dermatol doi: 10.1111/j.1346-8138.2009.00762.x contributor: fullname: Y Hamaguchi – volume: 78 start-page: 131 issue: 1 year: 2019 ident: 2360_CR13 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2018-213518 contributor: fullname: C Bergua – volume: 65 start-page: 258 issue: 1 year: 2013 ident: 2360_CR27 publication-title: Arthritis Rheum doi: 10.1002/art.37705 contributor: fullname: S Serratì – volume: 72 start-page: 450 issue: 3 year: 1988 ident: 2360_CR31 publication-title: Clin Exp Immunol contributor: fullname: J Rosenbaum – volume: 115 start-page: 407 issue: 2 year: 2005 ident: 2360_CR45 publication-title: J Clin Invest doi: 10.1172/JCI23025 contributor: fullname: TK Means – volume: 9 start-page: 544 issue: 9 year: 2013 ident: 2360_CR10 publication-title: Nat Rev Rheumatol doi: 10.1038/nrrheum.2013.110 contributor: fullname: G Nocturne – volume: 58 start-page: 2163 issue: 7 year: 2008 ident: 2360_CR38 publication-title: Arthritis Rheum doi: 10.1002/art.23486 contributor: fullname: D Kim – volume: 195 start-page: 83 year: 2018 ident: 2360_CR33 publication-title: Immunol Lett doi: 10.1016/j.imlet.2017.10.007 contributor: fullname: G Moroncini – volume: 20 start-page: 187 issue: 1 year: 2018 ident: 2360_CR14 publication-title: Arthritis Res Ther doi: 10.1186/s13075-018-1689-6 contributor: fullname: E Raschi – volume: 29 start-page: 174 issue: 2–3 year: 2007 ident: 2360_CR12 publication-title: J Autoimmun doi: 10.1016/j.jaut.2007.07.005 contributor: fullname: Y Katsumata – volume: 291 start-page: 261 issue: 2 year: 2002 ident: 2360_CR25 publication-title: Biochem Biophys Res Commun doi: 10.1006/bbrc.2002.6449 contributor: fullname: MA Raymond – volume: 390 start-page: 1685 year: 2017 ident: 2360_CR3 publication-title: Lancet. doi: 10.1016/S0140-6736(17)30933-9 contributor: fullname: CP Denton – volume: 14 start-page: 208 issue: 2 year: 2012 ident: 2360_CR11 publication-title: Arthritis Res Ther. doi: 10.1186/ar3787 contributor: fullname: A Ambrosi – volume: 15 start-page: 705 issue: 12 year: 2019 ident: 2360_CR15 publication-title: Nat Rev Rheumatol doi: 10.1038/s41584-019-0322-7 contributor: fullname: JHW Distler – volume: 6 start-page: 112 year: 2010 ident: 2360_CR4 publication-title: Nat Rev Rheumatol doi: 10.1038/nrrheum.2009.238 contributor: fullname: SI Nihtyanova – volume: 70 start-page: 187 issue: 3 year: 2018 ident: 2360_CR49 publication-title: Reumatismo. doi: 10.4081/reumatismo.2018.1049 contributor: fullname: MS Chimenti – volume: 40 start-page: 551 year: 1997 ident: 2360_CR21 publication-title: Arthritis Rheum doi: 10.1002/art.1780400322 contributor: fullname: N Del Papa – volume: 174 start-page: 5740 issue: 9 year: 2005 ident: 2360_CR26 publication-title: J Immunol doi: 10.4049/jimmunol.174.9.5740 contributor: fullname: P Laplante – volume: 17 start-page: 582 issue: 6 year: 2018 ident: 2360_CR29 publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2017.12.010 contributor: fullname: M Thiebaut – volume: 202 start-page: 1575 issue: 11 year: 2005 ident: 2360_CR42 publication-title: J Exp Med doi: 10.1084/jem.20051696 contributor: fullname: J Vollmer – volume: 70 start-page: 450 issue: 3 year: 2018 ident: 2360_CR28 publication-title: Arthritis Rheumatol. doi: 10.1002/art.40390 contributor: fullname: TE Taher – volume: 112 start-page: 533 issue: 3 year: 1998 ident: 2360_CR40 publication-title: Clin Exp Immunol doi: 10.1046/j.1365-2249.1998.00597.x contributor: fullname: LF Pan – volume: 4 start-page: 295 year: 2006 ident: 2360_CR18 publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2006.01753.x contributor: fullname: S Miyakis |
SSID | ssj0022924 |
Score | 2.5341227 |
Snippet | Abstract
Background
Consistently with their diagnostic and prognostic value, autoantibodies specific for systemic sclerosis (SSc) embedded in immune complexes... Background Consistently with their diagnostic and prognostic value, autoantibodies specific for systemic sclerosis (SSc) embedded in immune complexes (ICs)... Consistently with their diagnostic and prognostic value, autoantibodies specific for systemic sclerosis (SSc) embedded in immune complexes (ICs) elicited a... BACKGROUNDConsistently with their diagnostic and prognostic value, autoantibodies specific for systemic sclerosis (SSc) embedded in immune complexes (ICs)... Abstract Background Consistently with their diagnostic and prognostic value, autoantibodies specific for systemic sclerosis (SSc) embedded in immune complexes... |
SourceID | doaj pubmedcentral proquest gale crossref |
SourceType | Open Website Open Access Repository Aggregation Database |
StartPage | 1 |
SubjectTerms | Abnormalities Antibodies Antigens Arthritis Autoantibodies Biopsy Care and treatment Cell culture Deoxyribonucleic acid Development and progression Disease DNA Endothelial cells Endothelium Fibroblasts Fibrosis Immune complexes Immune response Lupus Observations Pathogenesis Penicillin Polyethylene glycol RNA polymerase Scleroderma Scleroderma (Disease) Systemic sclerosis Toll-like receptors Tumor necrosis factor-TNF |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NS91AEF-Kh9KLaKv41MoWCh7KYj422aQ3FUUK9tIK3pb9mNWALxFfHvQf6f_rzCZPjB68eN3dkN352plk5jeMfS9zvCMkSCEzG4SE4EQdMi-Uk6kplPEhNu27_F1eXMlf18X1s1ZflBM2wAMPhDuC0niTWC-V9xKqYNG_9w6dGkhKb-yAXpoWq2BqDLUyDCtWJTJVebRAS62oEjkRhJiOlmdyDUW0_tc2-WWe5LOL53yDrY8eIz8edrrJPkD7mX28HP-Jf2H__-DwA7U0mxtBhZOU_MPNsu-QaI3tKE2Qw9wCmhjPm5Y3VBICPCaTwz-cjNUjPXBoPdVj3aFIcm_maGl-ctNyIAxkHpGe6HFcwamPcXdDZrJZ8C7wAQ8aX7uIe8HRLXZ1fvb39EKMzRaEwximFxYJGoMRSSEg_Y-pa--McxLSYAOGgaX16J9JV9tQBfQcVAJFrqTMstQD5Ntsre1a2GE8gPNkGEIFqVS2MC7USQYqNxj1okc4Yz9WtNf3A6aGjrFIVeqBUxo5pSOndD5jJ8Sep5WEhx0HUEr0KCX6LSmZsUNiriatRVbiuYbiA9ww4V_pYzx5ptA5wtftT1aitrnp9Eo89KjtC02YfFVB3tiMfXuapicpg62FbklrijqXlSxwL2oiVpOTTWfa5jYifqsSHd1a7b4HKfbYp4wUgT6N1_tsrX9Ywld0rHp7EHXoEb4rJiQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Proquest Health and Medical Complete dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEBZpCqWX0ifdJikqFHooYr22bNm5lKQ0LIX00gb2JvQYpYasne56oX8k_zczsp3ULfQqyUjWjL6ZkebB2PsiQxkhQQqZ2iAkBCeqkHqhnFyYXBkfYtG-82_F8kJ-XeWrPbYcY2HIrXLExAjUvnV0Rz6nvGdlThJvbizdArhu_un6l6D6UfTOOhTTeMAeLlJUK5Cz1ere9EqrvrytRJsJRawcw2fKYr5FFFcUpZwIyqaOqDQRUTGT_794_bcP5R9C6ewpezJok_ykJ_8ztgfNc_bofHgvf8FuvmPzhsqdrY2goEpyDOJm17W4obVtyYWQw9oCwo_ndcNrChcBHh3N4Td2xsiSDjg0nmK1rpBduTdrRKFjbhoOlB-ZxyxQ9DmO4FTjuL0kCK23vA28zxWN027jWrD1Jbs4-_Lj81IMhRiEQ_umE7aAJBoqksxDequpKu-McxIWwQY0EQvrUXeTrrKhDKhVqATyTEmZpgsPkL1i-03bwGvGAzhPoBFKQGLY3LhQJSmozKBFjNrijH0c915f9_k2dLRTykL3lNJIKR0ppbMZOyXy3I2kXNmxod1c6uHoaSiMN4n1UnkvoQwWLUTvUC2GpPDG5jP2gYir6UQTX5khMAEXTLmx9An-eapQccLpDicj8SS6affIHnpAgq2-59sZe3fXTV-Sd1sD7Y7G5FUmS5njWtSErSZ_Nu1p6p8xG7gqUAmu1Jv_T37AHqfE4nQhXh2y_W6zgyNUpzr7Np6UW2HJIUg priority: 102 providerName: ProQuest |
Title | Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis |
URI | https://www.proquest.com/docview/2461850074/abstract/ https://search.proquest.com/docview/2459348455 https://pubmed.ncbi.nlm.nih.gov/PMC7654597 https://doaj.org/article/e6ada0bd47dd4e8fb164dc916e06dab5 |
Volume | 22 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Ja9wwFBZJCiGX0pVOmw4qFHooznhs2bJ7m4SEUJgQ2g7MTWh5SgwZO8wC_SP5v3lPtkPd3nrxQQuW_PSWT34LY5_zFHWEABGJxPhIgLdR6RMXSSumOpPa-VC0b36VXy7E92W23GNZHwsTnPatqU7qu9VJXd0G38r7lZ30fmKT6_mZzFHvl3Kyz_ZlmvYQvUNZSdlWshUIj1Cbij5SpsgnGxTYkgKS44gSp6MAOmKHKZVuiuV0oJhC_v5_pfTfnpN_qKKLF-x5Z0PyWbvWl2wP6lfscN79JX_NHn5i85qKnK10RKGU5A7E9W7b4GesTEOOgxxWBlDoOF7VvKIgEeDBvRx-Y2eIJ9kCh9pRhNYdHlLu9Aplzzeuaw6UFZmH3E80HUdwqmzc3JDgrDa88bzNEI2v3YS1YOsbtrg4_3V2GXXlFyKLqGYbmRziAE8EgUL6Q1OWzmprBUy98QgMc-PQYhO2NL7waEvIGLJUCpEkUweQvmUHdVPDO8Y9WEeiwheAdDGZtr6ME5CpRhyMNuKIfe2_vbpvs2yogE6KXLVEU0g0FYim0hE7JfI8jaQM2aGhWd-o7pwoyLXTsXFCOieg8AZxobNoDEOcO22yEftCxFXEx0hK3FcbjoALpoxYaoY7TySaS_i648FI5D877O6Ph-r4f6MoS1-RkX02Yp-eumkm-bTV0OxoTFamohAZrkUOjtVgZ8MeZImQA7xjgff_PfMDO0qIEeiGvDxmB9v1Dj6ifbU1Y-SqpRyzZ6fnV9c_xuGWYhx4DJ-LZPYIpQsrAw |
link.rule.ids | 230,315,733,786,790,870,891,2115,12083,21416,27957,27958,31754,31755,33779,33780,43345,43840,53827,53829 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA-6B-qL-Imrp0YQfJBy3TZtWl_kTu5Y9XYRvYN7C_mYnAW3Pbdd8B_x_3Um7a5WwdckJUlnMjO_ZD4Ye5mnqCMEiEgkxkcCvI1Kn7hIWjHTmdTOh6J9i2U-PxcfLrKL4cKtHdwqtzIxCGrXWLojP6C8Z0VGGu_t1feIqkbR6-pQQuM62xMpQpUJ2zs6Xn76vINcSdmXtRWIlVC1im3YTJEftCi9JUUnxxFlUUdpNFJNIYP_v3L6b9_JP5TRyR12e7Ai-WFP9rvsGtT32I3F8E5-n_38gs1rKnO20hEFU5JDENebrsEfWZmGXAc5rAyg2HG8qnlFYSLAg4M5_MDOEFHSAYfaUYzWN2RT7vQKpc8brmsOlBeZh-xP9DmO4FTbuLkk0Vm1vPG8zxGN07ZhLdj6gJ2fHJ-9m0dDAYbIIq7pIpNDHACKIFhIbzRl6ay2VsDMG4_QMDcObTZhS-MLj9aEjCFLpRBJMnMA6UM2qZsaHjHuwToSFr4AJIbJtPVlnIBMNSJhtBKn7PX236urPs-GCvikyFVPKYWUUoFSKp2yIyLPbiTlyA4NzfpSDUdOQa6djo0T0jkBhTeIDJ1Fcxji3GmTTdkrIq6ik4ykxH31AQm4YMqJpQ5x54lEgwmn2x-NxBNox91b9lCDBGjVb36dshe7bvqSvNpqaDY0JitTUYgM1yJHbDXa2binrr6GLOAyR-O3lI__P_lzdnN-tjhVp--XH5-wWwmxO12Kl_ts0q038BRNqs48G87NL02qIeE |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSKteeKMuFDASEgeU3WzivLiVwqo8tqoElSoulh_jEtFNVrtZCfE_-L_MOEnVlFuv9ljxaMbjmXjmG8ZepzHeEQJEICLtAgHOBIWLbJAZMVNJpqzzTfsWx-nRqfh8lpxdafXlk_aNLifVxXJSlT99buVqaaZ9ntj0ZHGYpXjvF9l0Zd30NruDZzYq-kC9i7Wiou1nKzBIwjtV9PUyeTrdoNnOqCw5DAg-Hc3QLhvF1MApzGaD68mj-P9vq6_nT165kOb32I-elTYP5ddk2-iJ-XMN5fFGvN5ndzs3lR-0JA_YLagestGie4h_xP5-w-E19VFbqoCqNSnjiKttU6OkSl1TbiKHpQa0a5aXFS-pDgW4z2CH3zjpS1Ya4FBZKgK7wHPArVqieXvHVcWBgJe5h5ei5UjBqXlyfU62udzw2vEWhBo_u_F7wdHH7HT-8fvhUdB1eAgMBk5NoFMIfQQkKO6kR6CisEYZI2DmtMPYM9UWnUJhCu1yh-5KFkISZ0JE0cwCxE_YTlVXsMe4A2PJGrkcUOg6UcYVYQRZrDDURjd0zN72gpWrFshD-gAoT2WrERI1QnqNkPGYvSfZX1ISCLcfqNfnshOPhFRZFWorMmsF5E5j6GkN-tsQplbpZMzekOZIMhWoJ8hXW_GAGybQLXmAnEcZemT4uf0BJR5xM5zudU92JmYjCQgwT8gFHLNXl9O0ktLmKqi3RJMUschFgnvJBjo74Gw4g5roYcY7zXt645Uv2ejkw1x-_XT85RnbjejA0f_4Yp_tNOstPEdvrtEv_Ln9B7m9Syc |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Scleroderma-specific+autoantibodies+embedded+in+immune+complexes+mediate+endothelial+damage%3A+an+early+event+in+the+pathogenesis+of+systemic+sclerosis&rft.jtitle=Arthritis+research+%26+therapy&rft.au=Raschi%2C+Elena&rft.au=Privitera%2C+Daniela&rft.au=Bodio%2C+Caterina&rft.au=Lonati%2C+Paola+Adele&rft.date=2020-11-09&rft.pub=BioMed+Central+Ltd&rft.issn=1478-6354&rft.eissn=1478-6362&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs13075-020-02360-3&rft.externalDocID=A642271903 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-6362&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-6362&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-6362&client=summon |